Find disease awareness content and relevant supporting materials
Observational Study on Biomarkers in Head and Neck Cancer (HNpr�dBio)
The aim of this clinical research project is to validate the prognostic impact of potential biomarkers on loco-regional control of locally advanced head and neck cancer after definitive or adjuvant radiochemotherapy.
Predictive Modelling for Patient Stratification According to Treatment-related Toxicity and Survival After Chemoradiation for Head and Neck Cancer (PRETOXIS)
Radiotherapy is an integral component of the current multimodality treatment approach in locally advanced head and neck cancer (HNC). There...
Presentation of efficacy and safety data from VERSATILE-002 phase II clinical trial in recurrent or metastatic head and neck cancer at ASCO 2022.- PDS Biotechnology.
PDS Biotechnology announced an upcoming poster presentation of preliminary data from its ongoing Phase II VERSATILE-002 clinical trial at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022 in Chicago and online.
Update on KESTREL phase III trial of Imfinzi with or without tremelimumab in the 1st-line treatment of recurrent or metastatic head and neck cancer.- AstraZeneca
The KESTREL Phase III trial for AstraZeneca’s Imfinzi (durvalumab) did not meet the primary endpoint of improving overall survival (OS) versus the EXTREME treatment regimen (chemotherapy plus cetuximab), a standard of care, in the 1st-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumours expressed high levels of PD-L1.